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Abstract
Background: Glioblastoma multiforme (GBM) is an invariably fatal central nervous system tumor
despite treatment with surgery, radiation, and chemotherapy. Further insights into the molecular
and cellular mechanisms that drive GBM formation are required to improve patient outcome.
MicroRNAs are emerging as important regulators of cellular differentiation and proliferation, and
have been implicated in the etiology of a variety of cancers, yet the role of microRNAs in GBM
remains poorly understood. In this study, we investigated the role of microRNAs in regulating the
differentiation and proliferation of neural stem cells and glioblastoma-multiforme tumor cells.
Methods:  We used quantitative RT-PCR to assess microRNA expression in high-grade
astrocytomas and adult mouse neural stem cells. To assess the function of candidate microRNAs
in high-grade astrocytomas, we transfected miR mimics to cultured-mouse neural stem cells, -
mouse oligodendroglioma-derived stem cells, -human glioblastoma multiforme-derived stem cells
and -glioblastoma multiforme cell lines. Cellular differentiation was assessed by immunostaining,
and cellular proliferation was determined using fluorescence-activated cell sorting.
Results: Our studies revealed that expression levels of microRNA-124 and microRNA-137 were
significantly decreased in anaplastic astrocytomas (World Health Organization grade III) and
glioblastoma multiforme (World Health Organization grade IV) relative to non-neoplastic brain
tissue (P < 0.01), and were increased 8- to 20-fold during differentiation of cultured mouse neural
stem cells following growth factor withdrawal. Expression of microRNA-137 was increased 3- to
12-fold in glioblastoma multiforme cell lines U87 and U251 following inhibition of DNA methylation
with 5-aza-2'-deoxycytidine (5-aza-dC). Transfection of microRNA-124 or microRNA-137 induced
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morphological changes and marker expressions consistent with neuronal differentiation in mouse
neural stem cells, mouse oligodendroglioma-derived stem cells derived from S100β-v-erbB tumors
and cluster of differentiation 133+ human glioblastoma multiforme-derived stem cells (SF6969).
Transfection of microRNA-124 or microRNA-137 also induced G1 cell cycle arrest in U251 and
SF6969 glioblastoma multiforme cells, which was associated with decreased expression of cyclin-
dependent kinase 6 and phosphorylated retinoblastoma (pSer 807/811) proteins.
Conclusion: microRNA-124 and microRNA-137 induce differentiation of adult mouse neural
stem cells, mouse oligodendroglioma-derived stem cells and human glioblastoma multiforme-
derived stem cells and induce glioblastoma multiforme cell cycle arrest. These results suggest that
targeted delivery of microRNA-124 and/or microRNA-137 to glioblastoma multiforme tumor cells
may be therapeutically efficacious for the treatment of this disease.
Background
MicroRNAs (miRNAs) are a class of small non-coding
RNAs that regulate diverse cellular processes through RNA
interference-based mechanisms. miRNAs are transcribed
as primary RNA transcripts (pri-miRNAs), processed in
the nucleus to smaller precursor hairpin structures (pre-
miRNAs), and then exported to the cytoplasm where they
are processed further by the Dicer nuclease to become
mature, functional miRNAs approximately 21 nucleotides
in length. Mature miRNAs, the endogenous equivalent of
short interfering RNAs (siRNAs), are then incorporated
into the RNA-induced silencing complex, which facilitates
their interaction with, and inhibition of, target messenger
RNAs (mRNAs) by translational repression or message
cleavage (as reviewed in [1]).
Since the initial discovery of miRNAs as developmental
mutants in Caenorhabditis elegans, their role as important
regulators of stem cell division and development in evo-
lutionarily divergent organisms has become increasingly
apparent. For example, functional ablation of the RNa-
seIII enzyme Dicer, resulting in the ablation of miRNA
biogenesis, disrupts the division of insect germline stem
cells [2] and mouse embryonic stem cells [3], and impairs
early embryonic development in zebrafish [4] and mice
[5]. It is also becoming increasingly evident that miRNAs
play important roles in cancer etiology. For example,
expression of the mir-17–92 miRNA cluster augments
tumor angiogenesis [6] and accelerates c-Myc-induced B-
cell lymphoma development in mice [7], and the let-7
miRNA transcriptionally regulates the ras oncogene [8]
and inhibits growth of lung adenocarcinoma cells [9].
Further, impairment of miRNA processing enhances cellu-
lar transformation and tumorigenesis [10], consistent
with observations that global down-regulation of miRNAs
occurs in multiple tumor types compared with normal tis-
sues [11].
Most recently, specific miRNAs have been implicated in
the differentiation of cultures derived from mouse embry-
onic stem (ES) cells and mouse tumors. For example,
expression of miR-124 and miR-9 increases during differ-
entiation of mouse ES cell-derived neural progenitors, and
experimental manipulation of miR-124 and miR-9
expression affects neural lineage differentiation in the ES
cell-derived cultures [12]. Up-regulation of miR-124 also
induces neuronal differentiation of mouse neuroblast-
oma cell lines CAD and Neuro2a and the mouse embryo-
nal tumor cell line P19 [13]. These results suggest that
miRNAs may be valuable therapeutic agents if they simi-
larly promote differentiation of human tumor cells and
tumor stem cells (TSCs).
The discovery of a rare, highly tumorigenic, self-renewing
sub-population of glioblastoma multiforme (GBM) cells
that express the cell surface marker cluster of differentia-
tion (CD) 133 (see [14,15]), the so-called GBM stem cell
population, suggests that therapeutic approaches that
effectively inhibit or kill CD133+ GBM stem cells may
lead to marked improvements in patient outcome. To this
end, it has recently been demonstrated that induction of
differentiation of CD133+ GBM cells by bone morphoge-
netic protein 4 can effectively inhibit intracerebral GBM
tumor growth in mice [16]. In light of the growing body
of evidence supporting a role for miRNAs in promoting
stem cell differentiation, we investigated the role of miR-
NAs in differentiation and proliferation of human GBM
stem cells, mouse oligodendroglioma tumor stem cells
(mOSCs) and normal adult mouse neural stem cells
(mNSCs), putative progenitors of adult gliomas [17]. Our
results show that miR-124 and miR-137 can induce neu-
ronal differentiation of OSCs and GBM stem cells and
inhibit proliferation of GBM cell lines. These results sug-
gest that miR-124 and miR-137 may be useful therapeutic
agents for the treatment of GBMs.
Methods
Primary human tissues
Fresh frozen primary human tissues were acquired from
the Brain Tumor Research Center tissue core at the Univer-
sity of California San Francisco (UCSF) in accordance
with the Committee on Human Research approved proce-BMC Medicine 2008, 6:14 http://www.biomedcentral.com/1741-7015/6/14
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dures. All samples were thoroughly reviewed by a neu-
ropathologist (S Vandenberg), and anaplastic
astrocytomas (AAs) and GBM tumors were confirmed to
contain at least 90% tumor. Non-neoplastic brain tissues
were derived from the temporal lobes of epileptic patient
surgeries and comprised primarily cortex with mild to
moderate reactive astrocytosis and neurons. For further
details about the samples see Additional file 1.
Quantitative reverse transcriptase polymerase chain 
reaction
Total RNA was extracted using the miR-Vana RNA isola-
tion system (Ambion, Austin TX). Expression of 192
human miRNAs was quantitated in human tissues using
TaqMan®  miRNA assays human panel-early access kit
(Applied Biosystems, Foster City CA). Expression of the
six high-grade astrocytomas (HGA)-miRNAs during NSC
differentiation was quantitated using individual TaqMan®
MicroRNA Assays. The comparative Ct (ΔΔCt) method
was used to determine the expression fold change.
Statistical analyses
Statistical analysis of miRNA expression in primary tissues
was performed on log2 transformed fold change data
using freely available R language. The limma package in
Bioconductor was used to compare the three types of pri-
mary tissues (glioses, AAs and GBMs). Moderated t-statis-
tics were obtained as described elsewhere [18] and P-
values were adjusted for multiple comparisons by control-
ling the false discovery rate. Changes were considered sig-
nificant if the false discovery rate was less than 0.05.
Demethylation and deacetylation experiments
U87 and U251 glioma cell lines were seeded at 1 × 105
cells per well of a six-well plate, incubated for 24 hours in
Dulbecco's Modified Eagle's Medium (DMEM) high glu-
cose 10% serum, and then supplemented with fresh
media containing 5-aza-dC (1 or 5 μM; Sigma-Aldrich) for
72 hours or trichostatin A (TSA) (100 ng/ml; Sigma-
Aldrich) for 12 hours. For the combination study, 1 or 5
μM 5-aza-dC was present for 72 hours and TSA was added
for the last 12 hours. The media containing drugs were
changed every 24 hours.
miRNA oligonucleotides
miRIDIAN miRNA mimic negative control (cel-miR-67)
and miRIDIAN miRNA mimics (mmu-miR-124, mmu-
miR-137) were purchased from Dharmacon (Lafayette,
CO) and validated using the pMIR-REPORT miRNA
Expression Reporter Vector System (Ambion, Austin, TX).
For results, see Additional file 2.
CDK6-3'UTR miR-137 reporter assays
Cyclin-dependent kinase 6 (CDK6)-3'UTR reporter assays
were performed in U251 cells. pMIR-REPORT vectors har-
boring CDK6-3'UTR sequences with wild type (WT) miR-
137 binding sites or mutated (MUT) miR-137 binding
sites were generated by cloning the following oligonucle-
otides into the HindIII and SpeI restriction sites of pMIR-
REPORT: CDK6-UTR-WT fw 5'-AGCTTGATCACA-
GAAATATTGCTAGCTGATACATATTATTGCATTTCAT-
AAAACTA CDK6-UTR-WT rv 5'-
CTAGTAGTTTTATGAAATGCAATAATATGTATCAGCTAG-
CAATATTTCTGTGATCA CDK6-UTR-MUT fw 5'-AGCTT-
GATCACAGAAATTAACGAAGCTGATACATATTATTGCAT
TTCATAAAACTA CDK6-UTR-MUT rv 5'-CTAGTAGTTT-
TATGAAATGCAATAATATGTATCAGCTTCGTTAATTTCT-
GTGATCA Cells were transfected with (1) miR-137 or cel-
miR-67-negative-control mimics (50 nM), (2) pMIR-
REPORT vectors containing WT or MUT miR-137 binding
sites (400 ng) and (3) pRL-SV40 (Promega) expressing
Renilla luciferase (400 ng) for normalization. Cells were
grown in high-glucose DMEM supplemented with 10%
fetal bovine serum, and luciferase measurements were
performed 48 hours post-transfection using the Dual-
Luciferase Reporter Assay System (Promega).
Establishment and transfection of mouse subventricular 
zone-NSCs
Adult mouse subventricular zone (SVZ)-NSC cultures
were derived and grown as described previously [19] with
a few modifications. SVZ microdissections from 2-month-
old CD-1 mice (Charles River Laboratories) were dissoci-
ated to a single cell suspension with 0.25% trypsin, 0.5
mM ethylene diamine tetraacetic acid (EDTA) and gentle
trituration. Cells were cleared on a 22% Percoll (Sigma)
step-gradient (2) and grown in proliferation medium
(DMEM/F12/N2), 5% fetal calf serum (FCS), 20 ng/ml
epidermal growth factor (EGF), 20 ng/ml basic fibroblast
growth factor (bFGF) and 35 μg/ml bovine pituitary
extract (all media and supplements from Invitrogen, Inc.).
Non-attached cells were collected after 1 day and replated
into a 35-mm tissue culture dish (Corning). After 7 to 10
days, the plate was hyperconfluent with SVZ-NSCs and
these were routinely passaged 1:2 with 0.25% trypsin and
0.5 mM EDTA. Cells were passaged at least six times
before use in experiments. Media was half-changed every
2 days and completely changed every 4 days. Differentia-
tion of SVZ-NSCs for the miRNA expression time course
was induced by removing EGF, FGF and FCS from the
media [19].
For transfection of miR-124/137 into SVZ-NSCs, 50,000
cells were plated into eight-well culture slides (BD Falcon
Biosciences) pretreated with 0.1 mg/ml poly-D-lysine
(Sigma) and 10 μg/ml laminin (Invitrogen) 24 hours
prior to transfection. A total of 100 nM miRIDIAN miRNA
mimics (50 nM each for miR-124 and miR-137 co-trans-
fections) were complexed with LipofectAMINE 2000 (Inv-
itrogen) and added directly to cells growing inBMC Medicine 2008, 6:14 http://www.biomedcentral.com/1741-7015/6/14
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proliferating medium. Transfection and proliferating
medium was removed 12 to 24 hours post-transfection
and cells were induced to differentiate as described above.
Growth and transfection of S100βv-erbB mouse tumor 
stem cells
Adult tumor stem cells were derived from a low-grade oli-
godendroglioma of a 120-day-old FVB/N transgenic
mouse expressing the v-erbB transgene under control of
the S100β promoter [20]. Tumor tissue was microdis-
sected from the surrounding normal brain and dissociated
to a single cell suspension with papain, gentle trituration
and filtration through a 40-μM mesh screen (Falcon).
Neurospheres were grown from single cells in Neurobasal
medium (Invitrogen) supplemented with 20 ng/ml EGF
(Sigma), 20 ng/ml bFGF (Peprotech) and B27 (Invitro-
gen) on low-adherent tissue-culture dishes (Corning).
After four passages, neurospheres were dissociated and
replated into 10-cm culture dishes (Corning) in prolifera-
tion medium (see above). These TSCs are self-renewing
and multi-potent and express markers for astrocytes (glial
fibrillary acidic protein, GFAP), neuronal progenitors
(Tuj1) and oligodendrocytic progenitors (NG2) under
differentiating conditions.
For miRNA transfections, 25,000 cells were plated into
eight-well pre-coated culture dishes (Nunc), 24 hours
prior to transfection. Transfections and differentiation
procedures were performed as described for SVZ-NSC cul-
tures.
Growth, CD133 sorting and transfection of early passage 
human GBM cells (SF6969)
Human GBM tissue was acquired by surgical removal after
informed consent at UCSF and washed with Hank's buff-
ered saline solution without magnesium and calcium.
Tumors were then enzymatically dissociated with papain
(Worthington) for 30 minutes at 37°C. After centrifuga-
tion and one wash with phosphate buffered saline, pH
7.4, cells were transferred to NBE media consisting of neu-
robasal media without retinoic acid (Invitrogen), N2 and
B27 supplements (0.5× each; Invitrogen), 20 ng/ml
human recombinant bFGF (Peprotech) and 20 ng/ml
human recombinant EGF (Sigma-Aldrich). Cells were
plated in ultra-low adherent plates (Corning). Medium
was changed every 3 to 5 days.
Cells cultured in suspension were dissociated using
accutase (Innovative Cell Technologies) for 30 minutes at
37°C. After one wash in RinseMACS buffer (Miltenyi Bio-
tech), cells were incubated with magnetic beads conju-
gated with an antibody against the CD133/1 epitope. The
cells were incubated with beads for 30 minutes at 4°C.
Thereafter, cells were washed with 20× RinseMACS buffer,
centrifuged and added on to large cell columns connected
to a pre-separation filter. Fluorescence-activated cell sorter
analyses confirmed a pure CD133- fraction and a highly
enriched CD133+ fraction.
For transfections, both CD133+ and CD133- cells were
plated (20,000 cells per well) in 24-well plates coated
with polyornithine and laminin. Cells were transfected
with miR-124 and/or miR-137 (100 nM) or a negative
control oligonucleotide for 4 hours using lipofectamine.
Cells were then washed and cultured for 10 days in NBE
media without growth factors.
Immunocytochemistry
Stem cell cultures were fixed, washed and preblocked
prior to incubation with primary antibodies (Tuj1, 1:500,
Covance Inc.; GFAP, rabbit polyclonal, 1:500, Dako Inc.;
microtubule-associated protein 2 (MAP2) ab, 1:500,
Sigma). Cells were then stained with Alexa488- or
Alexa594-conjugated secondary antibodies and the nuclei
counterstained with Hoechst 33258 (Molecular Probes)
or DAPI (Sigma).
Cell cycle analysis
Cell cycle analyses were conducted using the fluorescein
isothiocyanate BrdU Flow Kit following manufacturer's
recommendations (BD Pharmingen, San Diego, CA).
Immunoblotting
Immunoblotting was performed using standard protocols
with antibodies CDK6 (1:1000; Cell Signaling, Temecula,
CA), Phospho-Rb (1:1000; Cell Signaling Technology,
Temecula, CA), and β-actin (1:5000; Sigma, St Louis,
MO).
For more detailed information regarding experimental
methods, see Additional file 3.
Results
miR-124 and miR-137 are down-regulated in high-grade 
gliomas and up-regulated during adult NSC differentiation
To identify deregulated miRNAs that have not been previ-
ously implicated in GBM cells [21,22], we used quantita-
tive reverse transcriptase polymerase chain reaction (RT-
PCR; Taqman) to measure expression of 192 mature
miRNA sequences in human non-neoplastic brain tissues
(glioses), AAs (World Health Organization (WHO) grade
III) and GBMs (WHO grade IV). The comparative Ct
(ΔΔCt) method was used to determine the expression fold
change of each miRNA in tumor samples relative to
glioses (see Additional file 4). Briefly, the ΔCt of each
miRNA was determined relative to let-7a and miR-16,
endogenous control miRNAs that were robustly and
invariantly expressed across all samples (see Additional
file 5) and the average ΔCt of the four glioses was used as
the calibrator for the tumor samples. Consistent with pre-BMC Medicine 2008, 6:14 http://www.biomedcentral.com/1741-7015/6/14
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vious observations in GBMs, we observed recurrent up-
regulation of miR-10b [22] and miR-21 [21] in our sam-
ple set; miR-10b was up-regulated more than 100-fold in
two out of four AA and two out of four GBM tumors; miR-
21 was up-regulated 5- to 30-fold in two out of four AA
and all four GBM tumors. Also consistent with previous
studies on other tumor types [11], we observed a global
decrease of expression in AA and GBM tumors relative to
non-neoplastic brain tissue.
We next performed statistical analyses of our miRNA
expression data to identify novel miRNAs of interest in
HGAs (GBM and AA). For a summary of these analyses see
Additional file 6. As shown in Table 1, we found 35 miR-
NAs that were significantly deregulated (P < 0.05) in AA or
GBM tumors. Thirteen (37%) of these miRNAs were dif-
ferentially expressed in both tumor classes relative to
glioses, 16 (45%) were differentially expressed in GBM
tumors only, and 6 (17%) were differentially expression
in AA tumors only. We identified six miRNAs of particular
interest, miR-7, miR-124, miR-129, miR-137, miR-139
and miR-218, which were down-regulated in both AAs
and GBMs (Figure 1A, Additional file 8 and Table 1) at a
more stringent level of significance (P ≤ 0.01). We hereaf-
ter refer to these six miRNAs as HGA-miRNAs.
We observed that the majority of the HGA-miRNAs show
expression changes during, or have been implicated in,
differentiation of various cell lineages: miR-7 during pho-
toreceptor differentiation [23]; miR-124 and miR-137
during erythropoiesis [24]; miR-124 and miR-218 during
neuronal differentiation of embryonal carcinoma cell dif-
ferentiation [25]; miR-124 during neuronal differentia-
tion of ES cells [12]. To test whether expression of HGA-
miRNAs was altered during differentiation of adult NSCs,
putative precursor cells of high-grade gliomas [17], we
established early passage (passage 6) cultures of SVZ-NCS
as described [19]. This is a monolayer NSC culture system
in which growth factor withdrawal rapidly (within 2 to 4
days) induces a large number of neuroblasts that consti-
tute approximately 50% of the total cells after 3 to 4 days
of differentiation. Consistent with previous studies [19],
we observed a steady increase in the number of Tuj1+ neu-
roblasts over a 5-day differentiation time course (Figure
2A). In parallel cultures, we measured miRNA expression
every 24 hours for 5 days (Figure 2B). Expression of miR-
124 and miR-137, respectively, increased up to 8- and 24-
fold, expression of miR-129 and miR-139, respectively,
decreased up to 2- and 4-fold, and expression of miR-7
and miR-218 did not change appreciably.
Our differentiation studies in mNSCs suggested that
growth factor signaling, which is recurrently activated in
Table 1: Differentially expressed microRNAs in anaplastic astrocytoma and/or glioblastoma multiforme tumors relative to non-
neoplastic brain tissue
Glioblastoma multiforme and anaplastic astrocytoma Glioblastoma multiforme only Anaplastic astrocytoma only
Fold change 
glioblastoma 
multiforme
Fold change 
anaplastic 
astrocytoma
Ref Fold change 
glioblastoma 
multiforme
Ref Fold change 
anaplastic 
astrocytoma
Ref
Down-regulated Down-regulated Down-regulated
miR-7 34 13 miR-101 4 miR-125b 153 [22]
miR-31 17 9 miR-128a 27 [22] miR-126 7
miR-107 14 10 miR-132 7 miR-127 149
miR-124 57 26 miR-133a 17 miR-134 9
miR-124b 45 27 miR-133b 14
miR-129 43 27 miR-149 9 Up-regulated
miR-137 63 66 miR-153 12 miR-296 11
miR-138 27 12 [21] miR-154* 7 miR-320 5
miR-139 66 34 miR-185 5
miR-187 6 5 miR-29b 6
miR-203 13 4 miR-323 17
miR-218 40 16 miR-328 8
miR-330 18
Up-regulated
miR-10b 35 75 [22] Up-regulated
miR-21 7 [21,22]
miR-155 8
miR-210 7
P-values for all miRNAs are P < 0.05 for comparisons of miRNA expression in tumors versus glioses; for miRNAs in bold P < 0.01. References 
indicate high-grade astrocytoma miRNA expression studies in which miRNA has been described previously.BMC Medicine 2008, 6:14 http://www.biomedcentral.com/1741-7015/6/14
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miR-124 and miR-137 are down-regulated in anaplastic astrocytomas and glioblastoma multiformes and are up-regulated in  glioblastoma multiforme cell lines following treatment with DNA demethylating agents Figure 1
miR-124 and miR-137 are down-regulated in anaplastic astrocytomas and glioblastoma multiformes and are 
up-regulated in glioblastoma multiforme cell lines following treatment with DNA demethylating agents. (A) 
Expression of high-grade astrocytomas-microRNAs in individual tumor samples measured relative to let-7a (black dots) and 
miR-16 (white dots). Sample classes are glioses, anaplastic astrocytomas and glioblastoma multiformes. (B) Glioblastoma multi-
forme cell lines (U87 and U251) were treated with 5-aza-dC at 1 μM (Aza.1) or 5 μM (Aza.5) alone, trichostatin A (100 ng/ml) 
alone, or combinations of both agents. MicroRNA expression was measured relative to let-7a and normalized to vehicle con-
trol (dimethyl sulfoxide). Error bars represent standard deviation of triplicate polymerase chain reactions from a single experi-
mental set. Similar results were obtained in independent experiments (see Additional file 7).BMC Medicine 2008, 6:14 http://www.biomedcentral.com/1741-7015/6/14
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MiRNA expression during differentiation of subventricular zone-neural stem cells Figure 2
MiRNA expression during differentiation of subventricular zone-neural stem cells. (A) Marker expression during 
adult neural stem cell neurogenesis. Photomicrographs are shown of proliferating subventricular zone-neural stem cells cul-
tures in proliferation conditions (A)-(D), and following 1 day (E)-(H), 2 days (I)-(L), 3 days (M)-(P) and 4 days (Q)-(T) of 
mitogen deprivation. Phase images (A), (E), (I), (M), (Q) are shown with corresponding epifluorescent images showing 4'-6-dia-
midino-2-phenylindole-stained nuclei (B), (F), (J), (N), (R) and Tuj1 expression (C), (G), (K), (O), (S). Glial fibrillary acidic pro-
tein expression (D), (H), (L), (P), (T) is shown in parallel cultures. (B) Expression analysis of high-grade astrocytoma-
microRNAs during a 5-day differentiation time-course of subventricular zone-neural stem cells.BMC Medicine 2008, 6:14 http://www.biomedcentral.com/1741-7015/6/14
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HGAs, suppresses expression of miR-124 and miR-137. It
has also been shown that miR-124 expression is epigenet-
ically suppressed in a number of tumor types including
colorectal and breast cancers [26]. Further, miR-137 is
closely associated with a large CpG island [27], suggesting
that it may also be epigenetically silenced in tumors. We
tested, therefore, whether expression of miR-124 and
miR-137 could be activated in GBM cell lines following
treatment with 5-aza-2'-deoxycytidine (5-aza-dC), a DNA
methylation inhibitor and/or TSA, a histone deacetylase
inhibitor. MiRNA-124 expression increased around 2-fold
in U251 and U87 cells following combined treatment
with 5-aza-dC (5 μM) and TSA (Figure 1B and Additional
file 8). MiRNA-137 expression increased up to 8-fold in
GBM cell lines treated with 5-aza-dC, and up to 12-fold in
cells treated with both 5-aza-dC and TSA (Figure 1B and
Additional file 8). Expression of both miRNAs remained
relatively unchanged in cells treated with TSA alone (Fig-
ure 1B and Additional file 8). These data suggest that epi-
genetic modification of regulatory sequences in CpG
islands may contribute to miR-124 and miR-137 silencing
in GBMs.
miR-124 and miR-137 promote neuronal differentiation of 
adult NSCs
To test whether up-regulation of miR-124 and miR-137
promote differentiation of adult mNSCs, we transfected
proliferating mNSCs with double-stranded RNA oligonu-
cleotides corresponding to the mature sequences of each
miRNA. In each experiment, at least 80% to 90% transfec-
tion efficiencies were achieved. NSCs were maintained in
proliferation medium during transfection in which cells
generally have a spindle, non-neuronal morphology, with
high expression of GFAP, a stem cell and astrocyte marker,
but low expression of the neuronal marker Tuj1 (Figure
2A). Growth factors were withdrawn 12 to 24 hours fol-
lowing transfection and cells were allowed to differentiate
for 72 hours. Transfection of either miR-124 or miR-137
resulted in a 5-fold increase in the numbers of cells
stained with the neuronal marker Tuj1 relative to controls
(Figure 3A, B and 3C). Distinct morphological changes
were also apparent for each miRNA; miR-124 induced
neuritic branching of the cells whereas miR-137 induced
a rounded or trapezoidal cellular appearance with no neu-
ritic outgrowth (Figure 3A and 3B). Co-transfection of
miR-124 and miR-137 resulted in a near 2-fold increase in
Tuj1+ cells relative to miR-124 or miR-137 transfections
alone but did not promote neuronal morphologic charac-
teristics (Figure 3C). Finally, transfection of miR-124, but
not miR-137, resulted in a 2-fold decrease in the numbers
of GFAP-positive cells (Figure 3A and 3C). Thus, overex-
pression of miR-124 and miR-137 enhances neuronal-like
differentiation of adult NSCs in vitro.
miR-124 and miR-137 promote neuronal differentiation of 
brain TSCs
As we observed that expression of miR-124 and miR-137
is reduced in HGAs and that miR-124 and miR-137 pro-
mote differentiation of non-neoplastic adult mNSCs, we
tested next whether up-regulation of miR-124 and miR-
137 could promote differentiation of brain tumor-derived
stem cells. We first assessed differentiation of mOSCs
derived from S100β-v-erbB  transgenic mouse oligoden-
drogliomas [20]. MiRNA-124 is down-regulated in
human oligodendrogliomas [28], and both miR-124 and
miR-137 are down-regulated over 10-fold in S100β-v-erbB
tumor stem cells relative to mNSCs (Additional file 7).
Consistent with our observations in mNSCs, we observed
a significant increase in the numbers of cells that express
the neuronal marker Tuj1 following transfection with
miR-124, miR-137 or a combination of both miRNAs
(Figure 4A). Transfection with either miR-124 or miR-137
resulted in rounded or trapezoidal cellular morphology of
Tuj1-positive cells with reduced neuritic outgrowth. We
also observed that transfection of miR-124 and miR-137
reduced the numbers of GFAP-positive mOSCs (Figure
4A).
We tested next whether miR-124 and miR-137 could pro-
mote differentiation of human GBM stem cells. GBM cells
were isolated from a primary tumor (SF6969) and
expanded as tumor spheres in nonadherent plates. Cells
were sorted using magnetic beads conjugated to an anti-
body against CD133, a putative marker of GBM stem cells
[14,15]. Both CD133+ and CD133- cells were transfected
with miR-124 and/or miR-137 and then cultured for 10
days in NBE media without growth factors. Transfection
of miR-124 and/or miR-137 dramatically increased the
percentage of Tuj1-positive cells, and reduced the percent-
age of GFAP-positive cells and in both CD133+ and
CD133- GBM cell fractions (Figure 4B). Tuj1 was
expressed in cells with a neuronal morphology but also in
rounded cells and cells undergoing mitosis. The expres-
sion of GFAP-positive cells was confined to cells display-
ing typical morphology of type I and type II astrocytes.
To further investigate the role of miR-137 in neuronal dif-
ferentiation of GBM cells, we assessed expression of an
additional neuronal marker, MAP2, following overexpres-
sion of miR-137. Unsorted SF6969 GBM cells were trans-
fected with miR-137 and cultured for 10 days in NBE
media without growth factors. In addition to the expected
increase of cells positive for Tuj-1 after 10 days, we also
observed an evident increase in MAP2-postive cells fol-
lowing transfection of miR-137 (Figure 4C). Again, as in
mNSCs and oligodendroglioma tumor spheres, miR-137
induced rounded morphology with little evidence of neu-
ritic outgrowth (Figure 4C). Collectively, our results show
that in the absence of growth factor signaling, miR-124BMC Medicine 2008, 6:14 http://www.biomedcentral.com/1741-7015/6/14
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miR-124 and miR-137 promote neuronal differentiation of subventricular zone-neural stem cells Figure 3
miR-124 and miR-137 promote neuronal differentiation of subventricular zone-neural stem cells. (A) Epifluores-
cent images of subventricular zone-neural stem cells 72 hours after transfection with miR-124, miR-137 and control oligonucle-
otide. Cells were immunostained with Tuj1 and glial fibrillary acidic protein antibodies, nuclei were counterstained with 4'-6-
diamidino-2-phenylindole- and images are merged. Scale bar is 10 μm. (B) Phase contrast images of subventricular zone-neural 
stem cells 48 hours post-transfection by miR124 and miR137 and Tuj1 immunostaining of the same cultures 72 hours post-
transfection. (C) Quantification of percentage of Tuj1+ cells, Tuj1+ cells with neuronal morphology and glial fibrillary acidic 
protein+ cells 72 hours after transfection with miR-124, miR-137, both miR-124 and miR-137, control oligonucleotide or 
transfection reagent.BMC Medicine 2008, 6:14 http://www.biomedcentral.com/1741-7015/6/14
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Induction of neuronal differentiation of tumor-derived neural stem cells by miR-124 and miR-137 Figure 4
Induction of neuronal differentiation of tumor-derived neural stem cells by miR-124 and miR-137. (A) Epifluores-
cent images of tumor-derived neural stem cells 72 hours after transfection with miR-124, miR-137, control oligonucleotides 
and lipofectamine reagent alone. Cells were immunostained with Tuj1 and glial fibrillary acidic protein antibodies and DNA was 
stained with Hoechst 33258 reagent. The percentage of Tuj1- and glial fibrillary acidic protein-positive cells was quantified in 
each sample after transfection and staining and plotted against the total number of counted cells (n = 450). (C) Quantification 
of Tuj1+ and glial fibrillary acidic protein+ cells in primary glioblastoma multiforme cultures 10 days after transfection of miR-
124, miR-137 or control oligonucleotides. The inset shows a Tuj1+ cell with neuronal morphology from a miR-124 and/or 
miR-137 cotransfection. (D) Immunostaining with neuronal markers Tuj1 and microtubule-associated protein 2 10 days after 
miR-137 or negative control miR-transfections in glioblastoma multiforme lines maintained as neurospheres.BMC Medicine 2008, 6:14 http://www.biomedcentral.com/1741-7015/6/14
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and miR-137 enhance neuron-like differentiation of oli-
godendroglial and GBM TSCs.
miR-124 and miR-137 inhibit proliferation of GBM cell 
lines
Since exit from the cell cycle is required for induction of
differentiation, we tested whether miR-124 and miR-137
inhibit proliferation of GBM cells. Relative to control oli-
gonucleotides, transfection of miR-124 or miR-137
resulted in a marked reduction in the number of cells in
the S-phase of the cell cycle and a marked increase in the
number of cells in G0/G1 in U251 GBM cells (Figure 5A)
and early passage GBM cells derived from a newly diag-
nosed human GBM (Figure 5B). No reproducible differ-
ences were observed for cells in G2/M of the cell cycle, or
in cells undergoing apoptosis (sub G1) in any of the cell
lines examined (data not shown). Our data suggest that
miR-124 and miR-137 induce G0/G1 cell cycle arrest in
GBM cells.
miR-124 and miR-137 inhibit CDK6 expression and 
phosphorylated retinoblastoma levels in GBM cells
To ascertain the molecular mechanisms by which miR-
124 and miR-137 induce G0/G1 cell cycle arrest in GBM
cells, we assessed expression of CDK6, a regulator of the
cell cycle and differentiation (reviewed in [29]), following
transfection of these miRNAs to U251 cells. CDK6 is an
established target of miR-124 in HCT-116 colon cancer
cells [26], a predicted target of miR-137 (TargetScan and
PicTar), and has been functionally implicated in the
development of multiple malignancies. In independent
experiments we observed marked reductions of CDK6
transcript (Figure 6A) and CDK6 protein (Figure 6B) in
response to miR-124 and miR-137 transfection. Levels of
phosphorylated retinoblastoma (RB) (pSer 807/811), a
known target of CDK6 [30], were also reduced in response
to miR-124 and miR-137 transfection (Figure 6B).
To validate that the 3' UTR of CDK6 is a direct target of
miR-137, we used a luciferase reporter system in which
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme stem cells and induce cell G0/G1 cycle arrest Figure 5
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme stem cells and induce cell G0/G1 cycle 
arrest. Cell cycle analysis was conducted by fluorescence-activated cell sorter at 48 hours after transfection of 100 nM (final 
total microRNA concentration) miR-124, miR-137, miR-124 and miR-137 together or negative control oligonucleotides 
(neg#1, neg#2) to U251 (A) and SF6969 (B) glioblastoma multiforme cells. Cells were treated with bromodeoxyuridine for 30 
minutes, fixed, treated with fluorescein isothiocyanate-labeled antibromodeoxyuridine antibody and the DNA stain 7-amino-
actinomycin D and subject to flow cytometry. Values represent mean ± standard deviation of replicate experiments; *P < 0.05.BMC Medicine 2008, 6:14 http://www.biomedcentral.com/1741-7015/6/14
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the predicted miR-137 binding site of CDK6 was cloned
downstream of luciferase. A control reporter vector was
also developed in which the seed region of the miR-137
binding site was mutated (Figure 6C). Co-transfection of
U251 cells with a WT CDK6-3'UTR (CDK6-WT) reporter
and the miR-137 mimic resulted in a significant decrease
in luminescence (P < 0.0001) relative to cells co-trans-
fected with CDK6-WT and a negative control miRNA
mimic (Figure 6D). Mutation of the CDK6 miR-137 seed
region rendered the reporter construct insensitive to inhi-
bition by miR-137 (Figure 6D). Therefore, miR-137, in
addition to miR-124, is a direct inhibitor of CDK6.
Discussion
Identification of miRNAs in high-grade gliomas
To identify miRNAs that are recurrently deregulated in
high-grade gliomas, we used quantitative RT-PCR to pro-
file expression of 192 miRNAs in human non-neoplastic
brain tissues, AAs and GBMs. From our analyses, we iden-
tified a number of miRNAs that have been described pre-
viously in GBM tumors such as miR-10b (see [22]) and
the apoptosis regulator miR-21 (see [21,22,31]). We also
identified a number of miRNAs, including miR-124 and
miR-137, which have not been described in prior GBM
profiling studies. It remains unclear why miR-124 and
miR-137 were not detected previously in GBM tumors,
particularly in light of our results that show dramatic
expression decreases of miR-124 and miR-137 in GBMs
(and AAs) relative to non-neoplastic brain tissue, and
results that show clear down-regulation of miR-124
expression in human oligodendrogliomas [28], human
astroblastomas [32] and GBM cell lines [32,33].
CDK6 expression is inhibited by miR-124 and miR-137 in glioblastoma multiforme cells Figure 6
CDK6 expression is inhibited by miR-124 and miR-137 in glioblastoma multiforme cells. (A) Transfection of 100 
nM miR-124 or miR-137 reduces cyclin-dependent kinase 6 mRNA transcript levels by 50% in U251 cells at 48 hours relative 
to cells transfected with 100 nM control oligonucleotide. Cyclin-dependent kinase 6 expression was determined by TaqMan 
relative to control genes Gus (black bars), GAPDH (gray bars) and 18S (white bars). Values represent average +/- standard devi-
ation of independent experiments. (B) Cyclin-dependent kinase 6 protein expression is dramatically reduced as determined by 
western blotting following transfection of miR-124 or miR-137. Levels of phosphorylated RB (pSer 807/811) are also markedly 
reduced in response to miR-124 or miR-137 transfection. (C) miR-137 sequence in relation to the pMIR-REPORT vector con-
taining the predicted cyclin-dependent kinase 6 miR-137 binding site (wild type). Mutated bases (underlined) were also intro-
duced into the miR-137 seed region (boxed) of the cyclin-dependent kinase 6-3'UTR (mutated). Vertical lines denote Watson-
Crick base pairing. (D) Relative luminescence of U251 cells following transfection miR-137 or negative control microRNA in 
conjunction with wild type or mutated cyclin-dependent kinase 6 reporter constructs. *P < 0.0001.BMC Medicine 2008, 6:14 http://www.biomedcentral.com/1741-7015/6/14
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Another notable discrepancy is that of miR-221 expres-
sion, which was not overexpressed in any of the tumors
tested in our study, but was shown to be overexpressed in
five out of nine of GBMs studied by Ciafre et al. [22], and
has been shown to inhibit expression of the cell-cycle
inhibitor p27(Kip1) in GBM cells [34]. The most obvious
differences between our study and previous GBM profil-
ing studies are: (1) the control tissues, adult glioses from
epileptic surgeries, a routinely used control tissue for GBM
molecular profiling studies, versus normal human fetal
brain and macroscopically characterized surgical speci-
mens from the tumor periphery [21,22]; (2) profiling
technologies, TaqMan versus micro-array [21,22]. Future
profiling studies on larger numbers of patient samples
will help to resolve these apparent discrepancies.
Our expression analyses revealed a total of 35 miRNAs
that were differentially expressed between high-grade gli-
omas and non-neoplastic brain tissue (P < 0.05, Table 1).
A vast majority of these miRNAs were down-regulated (29
out of 35; 83%), which is consistent with observations
that miRNA expression is globally down-regulated in mul-
tiple tumor types [11]. Of the 35 miRNAs, we identified
six HGA-miRNAs, which were down-regulated in both AA
and GBM tumors at a more stringent degree of signifi-
cance (P < 0.01): miR-7, miR-124, miR-129, miR-137,
miR-139 and miR-218. Although we restricted further
analyses of these six miRNAs to miR-124 and miR-137
because of their elevated expression during adult NSC dif-
ferentiation (Figure 1B), assessments of the other HGA-
miRNAs may lead to novel insights into the biology of
high-grade gliomas. Similarly, assessments of the miRNAs
that were differentially expressed in AA tumors only or
GBM tumors only (Table 1) may shed light on the biolog-
ical differences underlying these different tumor grades.
It is important to note that our miRNA expression profil-
ing studies were conducted at the tissue level, not at the
cellular level, which has important implications for the
interpretation of our results. In particular, prior work [28]
has shown that miR-124 is only expressed in the neurons
of adult human brains, which indicates that our observed
decrease in miR-124 expression in HGAs is a likely conse-
quence of there being relatively fewer neurons in tumor
tissue compared with non-neoplastic glioses controls.
While this does not change our conclusions that miR-124
and miR-137 can induce mNSC-, mOSC- and human
GBM-derived stem cell (hGSC)-differentiation, it indi-
cates that in situ expression analyses of miRNAs in HGAs,
non-neoplastic adult brain tissue, and during fetal- and
post-natal development of the mammalian central nerv-
ous system will be an important component of studies
aimed at investigating the functions of miRNAs during
normal brain development and tumorigenesis.
We also note that in this study we analyzed 192 of the 533
known human miRNAs that are currently described in
miRBase, release 10.0 (see [35]), which reflects the rapid
pace of miRNA discovery since the inception of our
miRNA expression studies. It is likely that miRNAs of
potential significance to brain tumor biology have not
been assessed here. Examples of such miRNAs include
those that show enriched expression in brain tissue such
as miR-451 and miR-488 (see [32]) and miRNAs that have
been implicated in the etiology of other tumor types, such
as miR-346 in follicular thyroid carcinoma [36]. There-
fore, comprehensive miRNA expression studies are war-
ranted in large HGA tumor sets that are linked to clinical
data, such as survival and therapeutic response in order to
generate an in-depth assessment of the role of miRNAs in
brain cancer etiology and therapy.
Regulation of miR-124 and miR-137 expression
Our results reveal two potential mechanisms by which
miR-124 and miR-137 may be suppressed in stem cells
and/or tumor cells. The first mechanism is growth factor
signaling: removal of EGF, and FGF from the culture
media resulted in robust increases in miR-124 and miR-
137 expression in adult NSCs. Given that activation of
EGF [37], PDGF [38] and FGF [39] signaling pathways
have each been implicated in gliomagenesis, it is reasona-
ble to speculate that one mechanism by which growth fac-
tor signaling promotes brain tumor formation is through
suppression of miR-124 and/or miR-137 expression and
NSC/TSC differentiation. Further analyses are required to
determine the relative contributions of EGF-, FGF- and
PDGF-induced signaling on suppression of miR-124 and
miR-137 transcription in adult NSCs and GBM tumor
stem cells.
The second mechanism by which miR-124 and miR-137
expression may be suppressed in GBM stem cells is via
epigenetic modification of their transcriptional regulatory
sequences. Indeed, epigenetic modification of specific
miRNAs in other tumor types has been reported recently.
For example, miR-127, which is down-regulated in pros-
tate, colon and bladder tumors relative to matched nor-
mal tissues, is up-regulated in cell lines derived from these
tumor types following inhibition of DNA demethylation
and histone deacetylase [40]. Of particular interest to our
studies, miR-124 is hyper-methylated in over one-third of
colon, breast, lung, lymphoma and leukemia primary
tumors, and is up-regulated in breast (MCF-7) and colon
(HCT-116) cancer cell lines following DNA demethyla-
tion [26]. We observed that miR-137 expression increased
in GBM cell lines U87 and U251 following treatment with
the DNA demethylating agent 5-aza-dC (Figure 1B). Inter-
estingly, we did not observe an increase in miR-124
expression in either cell line following 5-aza-dC treat-
ment. Further analyses of miR-137 and miR-124 pro-BMC Medicine 2008, 6:14 http://www.biomedcentral.com/1741-7015/6/14
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moter sequence methylation in primary tumors, TSCs and
NSCs are warranted to establish the degree to which epi-
genetic mechanisms contribute to suppression of these
miRNAs in HGAs.
Regulation of differentiation and the cell cycle by miR-124 
and miR-137
Previous studies have demonstrated that miR-124 is up-
regulated during development of the rodent nervous sys-
tem [41,42], and during neuronal differentiation of
mouse ES cells [12], and mouse and human embryonal
carcinoma cells [25]. Further, neuronal differentiation is
enhanced following ectopic overexpression of miR-124 in
mouse ES cells [12], mouse neuroblastoma cells [13], and
mouse embryonal carcinoma cells [13]. Our results indi-
cate that overexpression of either miR-124 or miR-137
promotes neuron-like differentiation of non-neoplastic
adult (mNSCs), mOSCs and CD133+ hGSCs. Thus, our
study is the first to implicate miR-124 in neuronal differ-
entiation of post-natal NCSs and brain TSCs.
The ability of miR-124 to induce robust stem cell differen-
tiation appears to be dependent on cell type, developmen-
tal timing and other, as yet unidentified, factors. For
example, in mouse neuroblastoma cell lines CAD and
Neuro2a, ectopic up-regulation of miR-124 alone is suffi-
cient to induce neuron-like differentiation, whereas in
mouse embryonic carcinoma cells (P19), miR-124
enhances neuronal differentiation only in the presence of
retinoic acid, an established inducer of P19 neuronal dif-
ferentiation [13]. Investigations of miR-124 expression
and function during development of the embryonic chick
spinal cord have determined that the proneural activity of
miR-124 is, at best, subtle [43,44], suggesting that addi-
tional factors- and/or signals are required for robust neu-
rogenesis at this developmental stage. Our studies show
that miR-124 and miR-137 enhance neurogenesis of
mNSCs, mOSCs and hGSCs in the absence of growth fac-
tor signaling. Although we have not tested whether miR-
124 and miR-137 alone can induce differentiation of the
various stem cells tested in this study, transfection of miR-
124 or miR-137 alone was sufficient to induce G1 cell
cycle arrest in standard GBM cell lines (Figure 5A). How-
ever, cell cycle arrest was more pronounced in miR-124-
and miR-137-transfected GBM cells (SF6969) that were
deprived of growth factors (Figure 5B). Overall, the most
robust effects of miR-124 and miR-137 overexpression on
cellular differentiation and proliferation were observed in
growth factor-deprived human cells (Figures 4B and 5B).
Collectively, our results suggest that while miR-124 and
miR-137 have the capacity to induce alone cell cycle arrest
and differentiation in human GBM cells and stem cells,
abrogation of growth factor signaling enhances their
capacity to do so. Additional studies will be required to
address this hypothesis, and incorporation of additional
GBM and oligodendroglioma-neurosphere lines will be
required to address the general applicability of our results
in relation to the biology and therapeutics of these dis-
eases.
Recent studies have begun to shed light on the molecular
mechanisms by which miR-124 regulates differentiation
and proliferation. For example, miR-124 directly targets
PTBP1 (PTB/hnRNP I) mRNA, a global repressor of alter-
native pre-mRNA splicing in non-neuronal cells, resulting
in the transition from non-neuronal- to neuronal-specific
alternative splicing patterns [13]. miR-124 also directly
targets and suppresses expression of small C-terminal
domain phosphatase 1 (SCP1), an inhibitor of neuronal
gene expression [44]. Finally, miR-124 overexpression in
HCT-116 colon cancer cells inhibits the expression of
CDK6, an established target of miR-124 (see [26]). Our
studies revealed that miR-137, as well as miR-124, inhib-
ited expression of CDK6, a predicted target of both miR-
NAs. Further, as with miR-124a (see [26]), our results
show that miR-137 is a direct inhibitor of CDK6. Overex-
pression of miR-124 or miR-137 also reduced the expres-
sion of phosphorylated RB (Figure 6B), a downstream
target of CDK6 [30]. It is interesting to note that CDK6 is
known to regulate both cell cycle progression and differ-
entiation (reviewed in [29]), suggesting that mir-124- and
miR-137-mediated inhibition of CDK6 may, in part,
account for the observed effects on GBM cell proliferation
and differentiation in this study. Further investigations are
needed to define the relationship between CDK6 down-
regulation and cell cycle arrest and/or differentiation in
GBM stem cells, and to identify and characterize addi-
tional miR-124 and miR-137 target genes.
Therapeutic potential of miR-124 and miR-137
The ability of miR-124 and miR-137 to induce potent
antiproliferative and prodifferentiation effects in CD133+
and CD133- human GBM cells suggests their potential
value for treatment of this disease. RNAi-based therapeu-
tics holds great promise for the development of entirely
novel therapeutic strategies for disease treatment [45],
and early phase clinical trials using siRNAs are currently
underway [46]. While delivery of siRNAs or miRNAs to
the central nervous system is particularly challenging
because of the blood brain barrier, a number of promising
strategies have been developed recently to circumvent this
problem. These include intranasal delivery of oligonucle-
otides [47], lipid encapsulation and targeted delivery of
nucleic acids [48,49], and direct administration of thera-
peutic agents to brain tumor tissues by convection-
enhanced delivery [50,51]. Further testing of miR-124 and
miR-137 in pre-clinical models of GBM [52,53] in con-
junction with various delivery strategies will help define
their ultimate therapeutic potential for treatment of GBM.BMC Medicine 2008, 6:14 http://www.biomedcentral.com/1741-7015/6/14
Page 15 of 17
(page number not for citation purposes)
Conclusion
We have investigated the role of miRNAs in adult human
HGAs and hGSCs and in adult mNSCs and mOSCs. Our
studies showed, for the first time to the best of the authors'
knowledge, that miR-124 and miR-137: (1) are expressed
at significantly lower levels in GBM tumors relative to
non-neoplastic brain tissue; (2) are up-regulated during
neuronal differentiation of adult mNSCs induced by
growth factor withdrawal; (3) promote neuronal-like dif-
ferentiation of growth-factor-deprived mNSCs, mOSCs
and hGSCs; (4) promote G0/G1 cell cycle arrest in GBM
cells and growth-factor-deprived hGSCs; (5) inhibit
expression of CDK6 mRNA, CDK6 protein and phospho-
rylated RB in GBM cells. These results suggest that targeted
delivery of miR-124 and/or miR-137 to GBM tumor cells
may be therapeutically valuable for GBM disease treat-
ment.
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